Literature DB >> 9135413

Mitomycin C dissolved in a reversible thermosetting gel: target tissue concentrations in the rabbit eye.

K Ichien1, T Yamamoto, Y Kitazawa, A Oguri, H Ando, Y Kondo.   

Abstract

AIMS: To determine whether a new, reversible thermosetting gel enhances mitomycin C transfer to target ocular tissues in the rabbit eye.
METHODS: A 0.1 ml solution of mitomycin C containing 0.22 microgram, 2.9 micrograms, or 28 micrograms of the agent dissolved in a reversible thermosetting gel consisting of methylcellulose, citric acid, and polyethylene glycol was injected subconjunctivally in 30 New Zealand albino rabbits. Scleral and conjunctival tissues were excised at 0.5, 1, 2, 4, or 24 hours after the injection and mitomycin C concentrations in these tissues were determined by high performance liquid chromatography. The concentration over time was approximated to a single exponential curve, and initial mitomycin C concentrations, time constants, and half life values were determined. Finally, the areas under the curves (AUCs) between 0.5 and 24 hours were calculated.
RESULTS: The mitomycin C concentrations in the target tissues were dose dependent and decreased rapidly over 24 hours. Both the initial mitomycin C concentrations as well as AUCs in these eyes treated with mitomycin C, dissolved in a reversible thermosetting gel, were higher than those in eyes treated similarly in a previous study in which the gel was not used.
CONCLUSION: Applied subconjunctivally in the rabbit eye, mitomycin C dissolved in the reversible thermosetting gel enhanced transfer of the agent to the sclera and the conjunctiva.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135413      PMCID: PMC1721991          DOI: 10.1136/bjo.81.1.72

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Concentration change of fluorouracil in the external segment of the eye after subconjunctival injection.

Authors:  M Kondo; M Araie
Journal:  Arch Ophthalmol       Date:  1988-12

2.  Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium.

Authors:  S Hayasaka; S Noda; Y Yamamoto; T Setogawa
Journal:  Am J Ophthalmol       Date:  1988-12-15       Impact factor: 5.258

3.  Residual mitomycin C dosage in surgical sponges removed at the time of trabeculectomy.

Authors:  T Yamamoto; Y Kitazawa
Journal:  Am J Ophthalmol       Date:  1994-05-15       Impact factor: 5.258

4.  Mitomycin concentration in rabbit and human ocular tissues after topical administration.

Authors:  K Kawase; H Matsushita; T Yamamoto; Y Kitazawa
Journal:  Ophthalmology       Date:  1992-02       Impact factor: 12.079

5.  Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery.

Authors:  G L Skuta; C C Beeson; E J Higginbotham; P R Lichter; D C Musch; T J Bergstrom; T B Klein; F Y Falck
Journal:  Ophthalmology       Date:  1992-03       Impact factor: 12.079

6.  Scleritis after glaucoma filtering surgery with mitomycin C.

Authors:  S Fourman
Journal:  Ophthalmology       Date:  1995-10       Impact factor: 12.079

7.  Mitomycin as adjunct chemotherapy with trabeculectomy.

Authors:  S S Palmer
Journal:  Ophthalmology       Date:  1991-03       Impact factor: 12.079

8.  Trabeculectomy with mitomycin. A comparative study with fluorouracil.

Authors:  Y Kitazawa; K Kawase; H Matsushita; M Minobe
Journal:  Arch Ophthalmol       Date:  1991-12

9.  Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony.

Authors:  R M Nuyts; P C Felten; E Pels; C T Langerhorst; H C Geijssen; H E Grossniklaus; E L Greve
Journal:  Am J Ophthalmol       Date:  1994-08-15       Impact factor: 5.258

10.  Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up.

Authors:  G J Katz; E J Higginbotham; P R Lichter; G L Skuta; D C Musch; T J Bergstrom; A T Johnson
Journal:  Ophthalmology       Date:  1995-09       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.